Immunocore’s filing for a $100 million IPO has revealed a range of issues affecting the TCR bispecific immunotherapy developer, including a kickback scheme run by a former employee and a trademark row with Immatics.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,